Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan and Atorvastatin in Egyptian Rheumatoid Arthritis Patients
NCT03770702Phase 3Recruiting
- Start
- Oct 2018
- Primary completion
- Dec 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of candesartan, atorvastatin in rheumatoid arthritis (RA). Started Oct 2018; status: recruiting.
02
Drugs
candesartanatorvastatin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03770702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770702.